A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a RANK-L (NF-κΒ ligand) antagonist for cancer therapy or prophylaxis and uses therefor.
The Council of the Queensland Institute of Medical Research
发明人:
Dougall, Bill,Teng, Michele,Ahern, Elizabeth,Smyth, Mark
申请号：
AU2018280340
公开号：
AU2018280340A1
申请日:
2018.06.05
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
Disclosed are agents for treating or preventing cancers. More particularly, the present invention discloses therapeutic combinations comprising antagonists of receptor of NF-κB (RANK) ligand and immune checkpoint molecules in methods and compositions for treating or inhibiting the development, progression or recurrence of cancers, including metastatic cancers.
